JP2021527041A5 - - Google Patents
Info
- Publication number
- JP2021527041A5 JP2021527041A5 JP2020567772A JP2020567772A JP2021527041A5 JP 2021527041 A5 JP2021527041 A5 JP 2021527041A5 JP 2020567772 A JP2020567772 A JP 2020567772A JP 2020567772 A JP2020567772 A JP 2020567772A JP 2021527041 A5 JP2021527041 A5 JP 2021527041A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- pyrazino
- isoindole
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018090004 | 2018-06-05 | ||
| CNPCT/CN2018/090004 | 2018-06-05 | ||
| EP18193916.6 | 2018-09-12 | ||
| EP18193916 | 2018-09-12 | ||
| CN2019086019 | 2019-05-08 | ||
| CNPCT/CN2019/086019 | 2019-05-08 | ||
| PCT/EP2019/064323 WO2019233941A1 (en) | 2018-06-05 | 2019-06-03 | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527041A JP2021527041A (ja) | 2021-10-11 |
| JP2021527041A5 true JP2021527041A5 (enExample) | 2023-07-11 |
| JP7374130B2 JP7374130B2 (ja) | 2023-11-06 |
Family
ID=66793968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567772A Active JP7374130B2 (ja) | 2018-06-05 | 2019-06-03 | 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12157746B2 (enExample) |
| EP (1) | EP3802539B1 (enExample) |
| JP (1) | JP7374130B2 (enExample) |
| KR (1) | KR20210018818A (enExample) |
| CN (1) | CN112204028B (enExample) |
| AU (1) | AU2019280728A1 (enExample) |
| BR (1) | BR112020024782A2 (enExample) |
| CA (1) | CA3098291A1 (enExample) |
| CL (1) | CL2020003065A1 (enExample) |
| CO (1) | CO2020014677A2 (enExample) |
| CR (1) | CR20200584A (enExample) |
| IL (1) | IL279144A (enExample) |
| MA (1) | MA52747A (enExample) |
| MX (1) | MX2020012827A (enExample) |
| PE (1) | PE20210131A1 (enExample) |
| PH (1) | PH12020552092A1 (enExample) |
| SG (1) | SG11202011137SA (enExample) |
| TW (1) | TW202016111A (enExample) |
| WO (1) | WO2019233941A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12421240B2 (en) | 2019-10-31 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| WO2021094301A1 (en) * | 2019-11-12 | 2021-05-20 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| JP2023502087A (ja) | 2019-11-19 | 2023-01-20 | エフ．ホフマン－ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロ－１Ｈ－ピロロ［１，２－ａ］ピラジン化合物 |
| US12421229B2 (en) | 2019-12-03 | 2025-09-23 | Hoffmann-La Roche Inc. | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease |
| WO2022013136A1 (en) | 2020-07-14 | 2022-01-20 | F. Hoffmann-La Roche Ag | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
| TW202214632A (zh) * | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
| CN114057759B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
| CN116490506B (zh) * | 2020-11-26 | 2024-12-13 | 江苏恒瑞医药股份有限公司 | 稠合三环化合物、其制备方法及其在医药上的应用 |
| WO2023025109A1 (zh) * | 2021-08-23 | 2023-03-02 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
| CN114656363A (zh) * | 2022-03-28 | 2022-06-24 | 南京林业大学 | 一种钯催化芳香酯类化合物的合成方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4273773A (en) | 1979-09-24 | 1981-06-16 | American Home Products Corporation | Antihypertensive tricyclic isoindole derivatives |
| NZ551468A (en) | 2003-12-24 | 2010-05-28 | Biota Scient Management | Polycyclic agents for the treatment of respiratory syncytial virus infections |
| WO2011106276A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| SG11201509520QA (en) | 2013-05-24 | 2015-12-30 | Janssen Sciences Ireland Uc | Pyridone derivatives for the treatment of viral infections and further diseases |
| ES2670550T3 (es) | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| SG10202103278TA (en) * | 2013-10-14 | 2021-04-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| PT3889145T (pt) | 2015-12-17 | 2024-04-02 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| MX391344B (es) | 2016-07-30 | 2025-03-21 | Bristol Myers Squibb Co | Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9). |
| EP4198031A1 (en) | 2016-08-08 | 2023-06-21 | Merck Patent GmbH | Tlr7/8 antagonists and uses thereof |
| KR102519535B1 (ko) | 2016-09-09 | 2023-04-06 | 브리스톨-마이어스 스큅 컴퍼니 | 피리딜 치환된 인돌 화합물 |
| CR20190119A (es) | 2016-09-09 | 2019-06-03 | Novartis Ag | Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje |
| ES2965044T3 (es) | 2017-07-18 | 2024-04-10 | Merck Patent Gmbh | Antagonistas de TLR7/8 y sus usos |
| ES2921020T3 (es) | 2017-08-04 | 2022-08-16 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo |
| CN110997656B (zh) | 2017-08-04 | 2023-04-14 | 百时美施贵宝公司 | 用作tlr7/8/9抑制剂的取代的吲哚化合物 |
| FI3692040T3 (fi) | 2017-10-05 | 2023-03-29 | Glaxosmithkline Ip Dev Ltd | Kemiallisia yhdisteitä |
| CN111448190B (zh) | 2017-11-14 | 2023-09-26 | 百时美施贵宝公司 | 取代的吲哚化合物 |
| BR112020011668A2 (pt) | 2017-12-15 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de éter de indol substituído |
| FI3728252T3 (fi) | 2017-12-18 | 2023-10-18 | Bristol Myers Squibb Co | 4-atsaindoliyhdisteitä |
| WO2019126082A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | 6-azaindole compounds |
| CN111511729A (zh) | 2017-12-19 | 2020-08-07 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| JP7313354B2 (ja) | 2017-12-19 | 2023-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物 |
| BR112020012084A2 (pt) | 2017-12-19 | 2020-11-24 | Bristol-Myers Squibb Company | compostos de indol substituído úteis como inibidores de tlr |
| US11299501B2 (en) | 2017-12-20 | 2022-04-12 | Bristol-Myers Squibb Company | Diazaindole compounds |
| BR112020011984A2 (pt) | 2017-12-20 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de amino indol úteis como inibidores de tlr |
| CA3085942A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| JP2021507889A (ja) | 2017-12-22 | 2021-02-25 | ノバルティス アーゲー | ピラゾロピペリジン誘導体の新規な使用 |
| JP7407740B2 (ja) | 2018-05-18 | 2024-01-04 | ノバルティス アーゲー | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 |
| WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| TWI825144B (zh) | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
| WO2021094301A1 (en) | 2019-11-12 | 2021-05-20 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| BR112022009856A2 (pt) | 2019-11-26 | 2022-08-02 | Hoffmann La Roche | Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune |
-
2019
- 2019-06-03 KR KR1020207034855A patent/KR20210018818A/ko not_active Ceased
- 2019-06-03 JP JP2020567772A patent/JP7374130B2/ja active Active
- 2019-06-03 US US16/972,556 patent/US12157746B2/en active Active
- 2019-06-03 PE PE2020001875A patent/PE20210131A1/es unknown
- 2019-06-03 BR BR112020024782-0A patent/BR112020024782A2/pt not_active Application Discontinuation
- 2019-06-03 SG SG11202011137SA patent/SG11202011137SA/en unknown
- 2019-06-03 CA CA3098291A patent/CA3098291A1/en active Pending
- 2019-06-03 EP EP19729220.4A patent/EP3802539B1/en active Active
- 2019-06-03 WO PCT/EP2019/064323 patent/WO2019233941A1/en not_active Ceased
- 2019-06-03 CR CR20200584A patent/CR20200584A/es unknown
- 2019-06-03 AU AU2019280728A patent/AU2019280728A1/en not_active Abandoned
- 2019-06-03 CN CN201980035182.7A patent/CN112204028B/zh active Active
- 2019-06-03 MX MX2020012827A patent/MX2020012827A/es unknown
- 2019-06-03 MA MA052747A patent/MA52747A/fr unknown
- 2019-06-04 TW TW108119369A patent/TW202016111A/zh unknown
-
2020
- 2020-11-25 CL CL2020003065A patent/CL2020003065A1/es unknown
- 2020-11-26 CO CONC2020/0014677A patent/CO2020014677A2/es unknown
- 2020-12-01 IL IL279144A patent/IL279144A/en unknown
- 2020-12-04 PH PH12020552092A patent/PH12020552092A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527041A5 (enExample) | ||
| TWI854989B (zh) | 用於抑制shp2活性之雜雙環化合物 | |
| AU2023201522B2 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| JP2022504936A5 (enExample) | ||
| CN105294683B (zh) | Cdk类小分子抑制剂的化合物及其用途 | |
| JP2022527588A5 (enExample) | ||
| JP7374130B2 (ja) | 自己免疫疾患治療用の新規なテトラヒドロ－１Ｈ－ピラジノ［２，１－ａ］イソインドリルキノリン化合物 | |
| CN101528225B (zh) | 作为5ht3调节剂的2-氨基苯并噁唑羧酰胺 | |
| JP7511097B1 (ja) | Ｈｅｒ２変異阻害薬 | |
| JP2017524702A (ja) | ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用 | |
| CN112313228A (zh) | 用于治疗自身免疫性疾病的新型杂芳基杂环基化合物 | |
| JP2017531672A5 (enExample) | ||
| WO2013117645A1 (en) | Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases | |
| US20200079763A1 (en) | Quinoxaline and pyridopyrazine derivatives as a pi3kb inhibitors | |
| EP4061821A1 (en) | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease | |
| JP2023533807A5 (enExample) | ||
| TW201940473A (zh) | 作為多激酶抑制劑的胺基碳酸鹽及尿素化合物 | |
| EP3623369B1 (en) | Novel morpholinyl amine compounds for the treatment of autoimmune disease | |
| JP2023503165A (ja) | 自己免疫疾患の処置のための１，８－ナフチリジン－２－オン化合物 | |
| RU2020142969A (ru) | СОЕДИНЕНИЯ ТЕТРАГИДРО-1Н-ПИРАЗИНО[2,1- a]ИЗОИНДОЛИЛХИНОЛИНА ДЛЯ ЛЕЧЕНИЯ АУТОИММУННОГО ЗАБОЛЕВАНИЯ | |
| RU2021131710A (ru) | Соединения гексагидро-1h-пиразино[1,2-a]пиразина для лечения аутоиммунного заболевания | |
| US20260085077A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
| JP2024089651A (ja) | Ｈｅｒ２変異阻害薬 | |
| WO2025104123A1 (en) | Heterocyclic derivatives as janus kinase inhibitors | |
| NZ768960A (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |